Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
6.47
-0.01 (-0.15%)
Jun 27, 2025, 4:00 PM - Market closed

DAWN Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
161.92131.16----
Upgrade
Cost of Revenue
8.165.28----
Upgrade
Gross Profit
153.76125.88----
Upgrade
Selling, General & Admin
118.22115.4575.5461.2929.164.68
Upgrade
Research & Development
227.11222.7130.5285.6243.589.1
Upgrade
Operating Expenses
345.33338.15206.06146.9172.7413.78
Upgrade
Operating Income
-191.57-212.27-206.06-146.91-72.74-13.78
Upgrade
Interest Expense
------0.03
Upgrade
Interest & Investment Income
20.4319.717.194.750-
Upgrade
Other Non Operating Income (Expenses)
109.2109.22-0.04-0.02-0.02-30.03
Upgrade
EBT Excluding Unusual Items
-61.94-83.35-188.92-142.18-72.75-43.84
Upgrade
Other Unusual Items
--5----
Upgrade
Pretax Income
-61.94-88.35-188.92-142.18-72.75-43.84
Upgrade
Income Tax Expense
7.147.14----
Upgrade
Earnings From Continuing Operations
-69.08-95.5-188.92-142.18-72.75-43.84
Upgrade
Minority Interest in Earnings
----2.113.34
Upgrade
Net Income
-69.08-95.5-188.92-142.18-70.65-40.51
Upgrade
Preferred Dividends & Other Adjustments
----99.99-
Upgrade
Net Income to Common
-69.08-95.5-188.92-142.18-170.64-40.51
Upgrade
Shares Outstanding (Basic)
97938065376
Upgrade
Shares Outstanding (Diluted)
97938065376
Upgrade
Shares Change (YoY)
16.53%16.87%21.85%77.13%568.42%-6.67%
Upgrade
EPS (Basic)
-0.71-1.02-2.37-2.17-4.62-7.33
Upgrade
EPS (Diluted)
-0.71-1.02-2.37-2.17-4.62-7.33
Upgrade
Free Cash Flow
-89.87-80.28-147.08-109.9-48.54-13.58
Upgrade
Free Cash Flow Per Share
-0.92-0.86-1.84-1.68-1.31-2.46
Upgrade
Gross Margin
94.96%95.97%----
Upgrade
Operating Margin
-118.31%-161.84%----
Upgrade
Profit Margin
-42.66%-72.81%----
Upgrade
Free Cash Flow Margin
-55.50%-61.21%----
Upgrade
EBITDA
-189.21-210.71-206.03-146.85-72.72-13.77
Upgrade
EBITDA Margin
-116.85%-160.65%----
Upgrade
D&A For EBITDA
2.361.560.040.060.020.02
Upgrade
EBIT
-191.57-212.27-206.06-146.91-72.74-13.78
Upgrade
EBIT Margin
-118.31%-161.84%----
Upgrade
Revenue as Reported
161.92131.16----
Upgrade
Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q